Investors & Media

May 16, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

May 16, 2022 / May 16, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

5/11/22

BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
- End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) scheduled for June of 2022; Plan to initiate the Phase 3 program in the second half of 2022 - - Three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming American...
Read More
5/2/22

BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
LAVAL, Quebec --(BUSINESS WIRE)--May 2, 2022-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications,...
Read More
4/25/22

BELLUS Health to Participate in Multiple Upcoming Investor Conferences
LAVAL, Quebec --(BUSINESS WIRE)--Apr. 25, 2022-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications,...
Read More